Pulmonology

These new data highlight key points about the timeline of benefits for those who quit smoking cigarettes, including respiratory and cardiovascular benefits.

This news from the FDA followed a resubmission after the FDA’s complete response letter for the P2X3 receptor antagonist’s use in refractory chronic cough and unexplained cough.

For Lung Cancer Awareness Month, Lungcast speaks with Christy Fischer, a patient who's spent the last 17 years fighting late-stage cancer.

This new data indicates both the high mental health burden on this patient population as well as the usefulness of integrated behavioral health care teams in clinics with a pediatric specialty.

This new data suggests that hospital facilities in the US may need to plan for potentially atypical timing of bronchiolitis season once more for 2023.

This new research sheds light on the importance of follow-up meetings for young patients discharged from emergency departments.

Though primarily observational, this research’s biggest asset is its experimental design and its exploration of viral stimulus-induced bronchial epithelial cell responses from asthmatic donors being treated with tezepelumab.

This newly-developed prediction model evaluating CAP risk was noted as having demonstrated accuracy, strong discriminatory qualities, and practicability in clinical settings.

The marketing denial orders were due to what the FDA stated as insufficient data supporting the products' additional benefit for adults switching from smoking cigarettes to vaping or cessation.

This new data represents the first real-world, US-based data on this drug, demonstrating the efficacy and the safety indications of these clinical trials.

This new data may help clinicians not to over-treat or over-medicalize with infants that have a SARS-CoV-2 infection.

Amid the escalating threat of wildfires due to climate change, the medical and public health communities face an increasing responsibility to develop robust emergency response plans to safeguard patients and healthcare infrastructure.

This action represents the first occurrence of the FDA pursuing civil money penalties for the maximum amount against e-cigarette retailers for such an offense.

Granted a PDUFA date in March 2024, if approved, sotatercept would be a first-in-class medication to address the rare and progressive disease.

New research on the effects of the Canadian wildfires on asthma syndrome in patients sheds light on the downstream effects of ecological disaster on regions outside of those affected.

This new research concluded that the unclear nature of safety outcomes indicated additional research and enhanced monitoring of patients’ adverse events may be necessary.

The UT Health infectious disease specialist reviews new vaccine and treatment options, as well as the threat of an RSV-flu-COVID "triple-epidemic" in this winter season.

This new data expands upon limited current research on environmental elements that contribute to the extensive variation in symptoms and infection frequency seen in children.

This new Morbidity and Mortality Weekly Report on the CDC site indicates the importance of influenza vaccination, especially for at-risk populations.

This new research indicates that children with ARDS surviving discharge have a higher probability of readmission than was reported previously among the pediatric intensive care unit population.

At ERS International Congress 2023, new data related to use of sotatercept offered providers additional insight into the effects of the agent in people with PAH.

This research was the result of the first study assessing adaptive smoking cessation treatment within a clinical population using very few criteria for exclusion.

An analysis of more than 4000 adolescents and young adults in the US found those who more recently used tobacco products reported more symptoms than other users.

In the latest episode of Lungcast, the diagnosis, classifciation and treatment of PE—namely blood clots—is comprehensively dissected by the Lewis Katz School of Medicine clinician and investigator.

This new data supports the use and feasibility of clinicians using longitudinal tobacco cessation care in the lung cancer screening setting.